Immunological evaluation of E6E7 protein vaccine fused to Ubiquitin against cervical cancer induced by HPV16.

Author(s)

Liliane Maria Fernandes de Oliveira

• Document type: Master's Dissertation
• Press: São Paulo.
• Institution: Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB/SDI)
• Defense date: 2012-12-04

Examining board members

Paulo Lee Ho; Silvia Beatriz Boscardin; Enrique Mario Boccardo Pierulivo

• Advisor: Paulo Lee Ho

Abstract

Cervical cancer is the third most common cancer women worldwide and HPV16 infection is a major risk factor for its ethiopathogenesis. In this study we evaluated in mice the prophylactic and therapeutic potential of the E6E7 proteic vaccine, consisting of immunogenic HPV16 E6 and E7 epitopes, with or without Ubiquitin-fused (E6E7Ub and UbE6E7), against TC-1 tumor cells. The E6E7 vaccine conferred complete protection against tumor growth in previously immunized wild-type, CD4 knockout and TLR4 deficient mice challenged with TC-1 cells. However, immunization of previously challenged animals with TC-1 cells, Ubiquitin-fused antigens promoted tumor regression in 60% of mice against 0% in non-Ubiquitinfused antigens. Besides, the fusion of Ubiquitin at the N-terminus of the antigen (UbE6E7) seems to enhance polyubiquitination in vitro, this Ubiquitin fusion strategy promoted an effective immunotherapeutic response against the tumor, being promising for the development of therapeutic cervical cancer vaccines and also other types of tumor. (AU)

• FAPESP's process: 10/04490-4 - Evaluation of an E6 and E7 multiepitope fused or not to ubiquitin against HPV16 derived cervical cancer
• Grantee: Liliane Maria Fernandes de Oliveira
• Support Opportunities: Scholarships in Brazil - Master